Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts

Research site

Germany Im Kaelblesrain 1, 73430 Aalen, Germany

Hormone receptor positive HER2 negative breast cancer · Colon cancer stage II · Rectal cancer stage II
Adult patients

About Specializations

Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts in Aalen, Germany specialises in clinical trials of conditions such as Hormone receptor positive HER2 negative breast cancer, Colon cancer stage II, Rectal cancer stage II, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Im Kaelblesrain 173430 AalenGermany

Open in maps ↗

Recruiting now: no trials
Conditions studied: 3

More sites in Aalen Germany

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

2 clinical trials

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Registered drugNo placebo

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Technische Universitaet Dresden

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites